Fuda Cancer Hospital
Fuda Cancer Hospital
Chiny, Kanton
Small intestine cancer treatment cost in China typically runs from $14,500 to $26,500 for primary surgical interventions. Expenses depend on the disease stage, specific therapy protocols, and the hospital tier. International patients can expect 60% to 80% savings compared to the United States. Guangzhou and Xiamen are leading cities providing specialized oncological care for this condition.
Typical Small Intestine Cancer Treatment Costs in China
Bookimed Expert Insight: Late-stage patients find the best value at specialized centers like Fuda Cancer Hospital. They offer over 10 minimally invasive options, including NanoKnife and cryosurgery. This is ideal for those seeking alternatives to traditional chemotherapy. For cases requiring complex radiation, Xiamen Humanity Hospital provides advanced technologies like VMAT and SBRT. These JCI-accredited facilities offer high-tech care at competitive international rates.
| Chiny | Turcja | Austria | |
| Resekcja jelita cienkiego | od $14,500 | od $12,150 | od $25,000 |
| Radioterapia w raku jelita | od $10,500 | od $5,800 | od $6,971 |
| Radioterapia raka odbytnicy | od $11,500 | od $7,000 | od $12,000 |
| Hipec (Hipertermiczna Chemioterapia Dootrzewnowa) | od $22,500 | od $22,500 | od $40,000 |
| Chemioterapia w raku piersi | od $14,800 | od $1,200 | od $15,000 |
Państwo nie płacą za usługi Bookimed. Ceny leczenia raka jelita cienkiego odpowiadają cennikowi kliniki. Płatność dokonywana jest bezpośrednio w klinice po przyjeździe. Dostępna jest płatność w ratach.
Bookimed dba o Państwa bezpieczeństwo. Współpracujemy tylko z klinikami spełniającymi wysokie międzynarodowe standardy w leczeniu raka jelita cienkiego. Posiadają one wymagane licencje do obsługi pacjentów międzynarodowych na całym świecie.
Bookimed oferuje bezpłatną pomoc i wsparcie. Osobisty koordynator medyczny pozostaje w kontakcie przed, w trakcie i po podróży. Nie będą Państwo sami w innym kraju podczas leczenia raka jelita cienkiego.
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
Primary treatment for small intestine cancer in China centers on surgical resection and advanced minimally invasive therapies. High-volume oncology centers prioritize R0 resection, often using laparoscopic or robotic techniques for faster recovery. Specialized facilities also utilize local ablation and hyperthermic intraperitoneal chemotherapy to manage advanced cases.
Bookimed Expert Insight: Patient data highlights a significant trend at specialized facilities like Fuda Cancer Hospital in Guangzhou. While standard protocols follow surgery with chemotherapy, these centers successfully substitute systemic drugs with minimally invasive ablative technologies. This approach is particularly effective for stage 3 or 4 patients who cannot tolerate the toxicity of traditional chemo regimens.
Patient Consensus: Patients emphasize the importance of choosing tertiary cancer centers with high surgeon experience in rare gastrointestinal tumors. They note that securing a second pathology review and detailed molecular testing is vital for determining if immunotherapy is an option.
Tumor location within the small intestine directly dictates the surgical approach and complexity. Upper tumors in the duodenum often require intricate multi-organ procedures like the Whipple. Conversely, tumors in the jejunum or ileum typically allow for standard bowel resections and direct reattachment.
Bookimed Expert Insight: High-volume centers like Fuda Cancer Hospital in Guangzhou utilize advanced techniques like NanoKnife for tumors in anatomically complex areas. Our data shows these facilities often manage over 30,000 international patients. This specialized experience is critical for duodenal cases where traditional surgery is high-risk.
Patient Consensus: Patients note that tumors located higher in the intestine cause blockage symptoms much earlier. They emphasize asking surgeons exactly how many centimeters of the bowel will be removed.
Top Chinese oncology centers in Guangzhou and Beijing specialize in treating advanced or unresectable small intestine cancer. These JCI-accredited facilities utilize cryosurgery and NanoKnife to target inoperable tumors. Specialized multidisciplinary teams integrate hyperthermic intraperitoneal chemotherapy (HIPEC) with vascular intervention for complex cases.
Bookimed Expert Insight: Data shows Fuda Cancer Hospital has treated over 30,000 patients from 100 countries. Their focus shifts from traditional surgery to microwave hyperthermia and cryosurgery for late-stage cases. This specific focus on minimally invasive local destruction is a key differentiator for unresectable tumors.
Patient Consensus: Patients note it is vital to bring original pathology slides and imaging discs for re-staging. Seeking second opinions at high-volume academic hospitals helps confirm if a tumor is truly unresectable.
The 3C+P model for gastrointestinal cancers in China is a comprehensive multidisciplinary management strategy. It integrates traditional chemotherapy, traditional Chinese medicine, and supportive care with precision medicine. This protocol aims to reduce therapy side effects while targeting specific molecular markers in advanced tumors.
Bookimed Expert Insight: While various 3C+P versions exist, JCI-accredited facilities like Fuda Cancer Hospital emphasize technological integration. They combine traditional pillars with advanced minimally invasive therapies like Cryosurgery or NanoKnife. This high-volume expertise is critical for rare conditions like small intestine cancer. Centers like Xiamen Humanity Hospital further refine the model. They utilize precision radiotherapy techniques including IMRT and VMAT for abdominal malignancies. Patients should confirm which specific technologies are bundled into a center's 3C+P protocol before booking.
Patient Consensus: Patients note that small intestine cancer requires specific surgical expertise rather than just a general protocol label. Many emphasize bringing physical pathology slides and imaging CDs to ensure the multidisciplinary team has accurate data for planning.
Bookimed Expert Insight: While Chinese hospitals serve thousands of international patients, integration levels vary by facility. Elite centers like Fuda Cancer Hospital combine minimal interventions like cryosurgery with TCM consultation. This hybrid approach often attracts patients seeking alternatives when standard systemic chemotherapy feels too taxing.
Patient Consensus: Patients note that TCM is vital for emotional comfort and improving appetite during recovery. Most emphasize using herbs only as an add-on to surgery to avoid dangerous delays.